Publication: Biological activity evaluation and molecular docking study of chromone derivatives as cyclooxygenase-2 inhibitors
Issued Date
2017-03-01
Resource Type
ISSN
15548120
10542523
10542523
Other identifier(s)
2-s2.0-85009740552
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Medicinal Chemistry Research. Vol.26, No.3 (2017), 662-671
Suggested Citation
Chirattikan Maicheen, Narumol Phosrithong, Jiraporn Ungwitayatorn Biological activity evaluation and molecular docking study of chromone derivatives as cyclooxygenase-2 inhibitors. Medicinal Chemistry Research. Vol.26, No.3 (2017), 662-671. doi:10.1007/s00044-017-1786-0 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42224
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Biological activity evaluation and molecular docking study of chromone derivatives as cyclooxygenase-2 inhibitors
Other Contributor(s)
Abstract
© 2017, Springer Science+Business Media New York. A series of chromone derivatives have been evaluated as potential cyclooxygenase-2 (COX-2) inhibitors. The four most potent compounds, 48, 41, 39, and 35 displayed IC50values of 3.30, 6.86, 7.36 and 7.46 µM, respectively. Compounds 35 and 38 showed higher selectivity for COX-2 (selectivity index, SI = 7.48 and 5.46, respectively) than celecoxib (SI = 4.17 in the same test) whereas compound 39 showed comparable selectivity (SI = 4.19) to celecoxib. The molecular volumes of compounds 35 (312.84 Å3) and 38 (314.18 Å3) were similar to celecoxib (299.28 Å3) but larger than ibuprofen (211.83 Å3). Docking results were in good agreement with the experimental biological data in terms of evaluation of binding energy and binding mode. Compounds 35, 38, and 39 had higher binding affinity against COX-2 (binding energy between −9.77 and −11.42 kcal/mole) than COX-1 (binding energy between −6.28 and −7.88 kcal/mole). These three chromone compounds also displayed active conformation in the same orientation as that of celecoxib. Thus, compounds in this series has the potential to be a new class of selective COX-2 inhibitor.